CDTX - Cidara Therapeutics, Inc.
3.92 +0.07 (1.76%)
After hours: 4:11PM EDT
| Previous Close | 4.00 |
| Open | 4.00 |
| Bid | 3.80 x 300 |
| Ask | 4.20 x 400 |
| Day's Range | 3.80 - 4.05 |
| 52 Week Range | 3.70 - 8.80 |
| Volume | 162,952 |
| Avg. Volume | 251,798 |
| Market Cap | 79.969M |
| Beta | 2.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.18 |
| Earnings Date | May 12, 2017 - May 15, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.81 |
- Business Wire•15 days ago
Cidara Therapeutics to Present Rezafungin Data at the European Congress of Clinical Microbiology and Infectious Diseases 2018 Meeting
Cidara Therapeutics, Inc. , a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies of its lead antifungal rezafungin will be presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases to be held in Madrid, Spain, April 21-24, 2018.
- GlobeNewswire•29 days ago
Cidara Therapeutics Provides Clinical Data Updates for its Lead Antifungal Rezafungin
Additional data and analyses from STRIVE Phase 2 clinical trial confirm positive efficacy results in both rezafungin arms. Definitive Phase 1 QT clinical trial showed no cardiac abnormalities. SAN DIEGO, ...
- ACCESSWIRE•29 days ago
Blog Exposure - Cidara Therapeutics Released Positive Top-line Results from Phase-2 STRIVE Trial Assessing its Lead Antifungal Rezafungin
Stock Monitor: BioTime Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Cidara Therapeutics, Inc. (NASDAQ: CDTX ). If ...
- Zacks•last month
Options Traders Expect Huge Moves in Cidara Therapeutics (CDTX) Stock
Surging implied volatility makes Cidara Therapeutics (CDTX) stock lucrative to the option traders.
- MarketWatch•last month
Cidara Therapeutics' stock soars toward 13-month high after positive drug trial results
Shares of Cidara Therapeutics Inc. shot up 14% toward a 13-month high in premarket trade Monday, after the biotechnology company said its lead antifungal drug candidate met all of its primary objectives ...
- GlobeNewswire•last month
Cidara Therapeutics Reports Positive Topline Results from Phase 2 STRIVE Trial of Lead Antifungal Rezafungin
Favorable safety, tolerability, and efficacy observed in novel once-weekly echinocandin for difficult-to-treat invasive fungal infections. Phase 3 studies for both treatment and prevention on track to ...
- GlobeNewswire•last month
Cidara Therapeutics to Present Rezafungin Data at the European Society for Blood and Marrow Transplantation 2018 Meeting
SAN DIEGO, March 08, 2018-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that two rezafungin abstracts have been accepted ...
- GlobeNewswire•2 months ago
Cidara Announces Appointment of Chrysa Mineo as Independent Director
SAN DIEGO, March 01, 2018-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of Chrysa Mineo to the company’ ...
- Associated Press•2 months ago
Cidara Therapeutics reports 4Q loss
The San Diego-based company said it had a loss of 69 cents per share. The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a ...
- GlobeNewswire•2 months ago
Cidara Provides Corporate Update and Reports Fourth Quarter and Full Year 2017 Financial Results
SAN DIEGO, Feb. 27, 2018-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months and full ...
- PR Newswire•3 months ago
The Antimicrobials Working Group Announces the Appointment of Dr. Michael Dunne as Vice Chair
WASHINGTON , Jan. 30, 2018 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today that Michael Dunne , M.D., Chief Scientific Officer of Iterum Therapeutics, has been appointed as Vice ...
- GlobeNewswire•3 months ago
Cidara Therapeutics Announces Presentations at the 8th Advances Against Aspergillosis Conference and 2018 BMT Tandem Meeting
SAN DIEGO, Jan. 29, 2018-- Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its ...
- GuruFocus.com•3 months ago
2018 Could Be Hallmark Year For These Two Antifungal Companies
Cidara will be completing Phase II trials for antifungal candidate rezafungin this quarter, followed by Scynexis. If approved, the drugs will compete with Merck, Astellas, and Pfizer.
- Thomson Reuters StreetEvents•5 months ago
Edited Transcript of CDTX earnings conference call or presentation 8-Nov-17 9:05pm GMT
Q3 2017 Cidara Therapeutics Inc Earnings Call
- Associated Press•5 months ago
Cidara Therapeutics reports 3Q loss
The San Diego-based company said it had a loss of 73 cents per share. The results beat Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss ...
- ACCESSWIRE•5 months ago
Cidara Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 8, 2017 / Cidara Therapeutics, Inc. (NASDAQ: CDTX ) will be discussing their earnings results in their Q3 Earnings Call to be held on November 8, 2017 at 4:05 PM Eastern ...
